Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards starts US SFA (superficial femoral artery) trials for LifeStent:

This article was originally published in Clinica

Executive Summary

Edwards Lifesciences has begun a US trial to assess its self-expanding stent, LifeStent NT, as a treatment for peripheral vascular disease. The RESILIENT study, which will involve around 220 patients at up to 25 medical centres throughout the country, differs from similar investigations because it is intended to demonstrate superiority, rather than equivalence, of the device over angioplasty in treating blockages in the superficial femoral artery (SFA) and popliteal artery, says the Irvine, California firm. The LifeStent system comprises a helical structural scaffold designed to withstand the continual bending and flexing experienced in the SFA. The company, which is also looking to CE-mark the product in Europe for the peripheral vascular disease indication, has already received US market clearance to use the device for treating biliary obstructions.

You may also be interested in...



Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.

Topics

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel